{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-22-023827","form_type":"8-K","ticker":"NKTX","cik":"0001787400","company_name":"Nkarta, Inc.","filed_at":"2022-11-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:52.119286+00:00","generated_at":"2026-06-22T01:46:13.075114+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Nkarta Q3 2022 net loss $28.3M; cash $395.1M; NKX019 dose expansion opened","bullets":["Net loss of $28.3M ($0.58 per share); R&D expense $23.4M, G&A $6.8M.","Cash, equivalents, and investments $395.1M; expected to fund operations into 2025.","NKX019 dose expansion cohorts opened; clinical update expected by year-end 2022.","NKX101 data for r/r AML timeline pushed to first half of 2023.","SITC presentations on NKX019+CD20 mAb combination and scalable NK cell manufacturing."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-22-023827","json":"https://secwatch.observer/filing/0000950170-22-023827.json","markdown":"https://secwatch.observer/filing/0000950170-22-023827.md","text":"https://secwatch.observer/filing/0000950170-22-023827.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1787400/000095017022023827/0000950170-22-023827-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1787400/000095017022023827/nktx-20221109.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T01:46:13.075114+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"340687bc93227d408bfe39227f01c0cb79c94789","claim":"Nkarta, Inc. reported financial results for the third quarter ended September 30, 2022.","evidence_excerpt":"On November 9, 2022, Nkarta, Inc. (the “Company”) issued a press release announcing the Company’s financial results for the third quarter ended September 30, 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1787400/000095017022023827/0000950170-22-023827-index.htm","confidence":0.7,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the third quarter ended September 30, 2022"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}